Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2020-11-02 Regulatory Filings
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a Form F-6 Registration Statement filed with the SEC, which is used for registering American Depositary Shares (ADSs) evidenced by American Depositary Receipts (ADRs). It includes details about the securities to be registered, the deposit agreement, and signatures of company officers and depositary representatives. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration under the Securities Act of 1933. The document is lengthy (over 13,000 characters) and contains the full registration statement, not just an announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-11-02 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is explicitly titled 'PDMR DEALING NOTIFICATION' (Person Discharging Managerial Responsibilities Dealing Notification). It details a transaction involving a Director (Dr. John LaMattina) transferring shares for nil consideration. This type of insider transaction report directly corresponds to the definition of Director's Dealing. The RNS Number and the mention of the London Stock Exchange confirm it is a regulatory filing, but the specific content points directly to the 'DIRS' category.
2020-11-02 English
PureTech Files Publicly for Nasdaq Listing
Regulatory Filings Classification · 98% confidence The document is an announcement released via RNS (RNS Number : 4037D) by PureTech Health PLC on October 28, 2020. The core subject is the 'Public Filing of Registration Statement on Form 20-F for Planned U.S. Listing on Nasdaq Global Market'. This filing relates to capital structure changes (potential U.S. listing/ADS trading) and the filing of a specific regulatory document (Form 20-F) with the SEC. Since the document is an announcement about a filing/corporate action rather than the full financial report (10-K, IR) or a specific capital change notice (SHA, CAP), and it is distributed via RNS, it fits best under the general regulatory announcement category, or potentially Capital/Financing Update (CAP) due to the nature of the news. However, the primary action described is the filing of a registration statement, which is a regulatory event announcement. Given the options, 'CAP' (Capital/Financing Update) is highly relevant because the entire announcement centers on a financing/listing strategy. Alternatively, 'RNS' (Regulatory Filings) is the general catch-all for such announcements distributed via the RNS system. Since the content is specifically about a major financing/listing strategy (U.S. Listing), CAP is more descriptive than the generic RNS, although RNS is also plausible as it is an RNS release. I will classify it as CAP because the substance is a capital market event announcement, which is a specific type of regulatory disclosure.
2020-10-28 English
20FR12B
Annual Report Classification · 100% confidence The document is a Form 20-F filed with the U.S. Securities and Exchange Commission (SEC), which is an annual report filed by foreign private issuers. It includes detailed sections such as identity of directors, senior management, financial information, risk factors, and financial statements. The presence of comprehensive financial and operational data, along with the SEC form designation 20-F, indicates this is a full annual report covering company activity and financial performance for the fiscal year. The document length (15,000 characters) and detailed table of contents further support this classification. Therefore, the filing type corresponds to an Annual Report (10-K equivalent for foreign issuers).
2020-10-27 English
Akili Presents New Data on EndeavorRx at AACAP
Environmental & Social Information Classification · 99% confidence The document is an announcement released via RNS (RNS Number: 7057C) on October 21, 2020. It details that PureTech Health's Founded Entity, Akili, announced the presentation of new outcome data for its digital therapeutic, EndeavorRx™, at the AACAP 2020 Virtual Annual Meeting. The text is structured as a press release, summarizing key findings and referencing external presentations/posters. Since this is an announcement about data presentations and clinical trial results, and it is distributed via the RNS system, it fits best under the general Regulatory Filings category (RNS), as it is not a full Earnings Release (ER), Interim Report (IR), or a specific management/board change announcement. It is a general corporate update distributed through a regulatory channel.
2020-10-21 English
Vor Appoints Biotech Leader Matt Patterson to BOD
Regulatory Filings Classification · 98% confidence The document is an announcement released via RNS (Royal National System, indicated by 'RNS Number' and 'This information is provided by Reach, the non-regulatory press release distribution service of RNS'). The content explicitly details the appointment of a new director (Matthew R Patterson) to the Board of Directors of a 'Founded Entity' (Vor Biopharma) of the reporting company (PureTech Health PLC). This type of announcement—a change in senior management or board composition—directly corresponds to the definition of 'Board/Management Information' (MANG). Although it is distributed via RNS, the specific content is not a general regulatory filing or a report announcement, but a specific corporate event disclosure.
2020-10-20 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.